Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an <i>NRG1</i> Fusion-Reference-Cited by-同舟云学术

Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion

Published:2022-11 Issue:6 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Thavaneswaran Subotheni¹²³^ORCID,Chan Wei Yen¹^ORCID,Asghari Ray⁴,Grady John P.²^ORCID,Deegan Maegan⁵^ORCID,Jansen Valerie M.⁵,Thomas David M.¹²

Affiliation:

1. The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia

2. Garvan Institute of Medical Research, St Vincent's Clinical School, Faculty of Medicine, UNSW, Darlinghurst, NSW, Australia

3. NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia

4. Cancer Therapy Centre, Bankstown-Lidcombe Hospital, Bankstown, NSW, Australia

5. Elevation Oncology, Inc, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.22.00263

Reference42 articles.

1. Detection of NRG1 Gene Fusions in Solid Tumors

2. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents

3. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer

4. Detection of NRG1 Fusions in Solid Tumors: Rare Gold?

5. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases;Pharmaceutics;2024-07-02

2. Fusion genes in pancreatic tumors;Trends in Cancer;2024-05

3. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs;Cancer Drug Resistance;2024-04-29

4. Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors;Global Medical Genetics;2024-01

5. Advancements in Systemic Therapy for Pancreatic Cancer;American Society of Clinical Oncology Educational Book;2023-05